×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NYSEAMERICAN:NNVC

NanoViricides Stock Forecast, Price & News

$1.89
+0.01 (+0.53%)
(As of 07/1/2022 03:24 PM ET)
Add
Compare
Today's Range
$1.85
$1.89
50-Day Range
N/A
52-Week Range
$1.04
$7.86
Volume
107 shs
Average Volume
59,654 shs
Market Capitalization
$21.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

NanoViricides MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
3.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.43 out of 5 stars

30 days | 90 days | 365 days | Advanced Chart

Receive NNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter.

NanoViricides logo

About NanoViricides (NYSEAMERICAN:NNVC) Stock

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.

NNVC Stock News Headlines

Nanomaterials Global Market Report 2022 - Yahoo Finance
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:NNVC
Previous Symbol
NYSEMKT:NNVC
Employees
17
Year Founded
N/A

Company Calendar

Last Earnings
5/17/2022
Today
7/05/2022
Fiscal Year End
6/30/2023

Profitability

Net Income
$-8,820,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.60 per share

Miscellaneous

Free Float
11,041,000
Market Cap
$21.84 million
Optionable
Optionable
Beta
0.58














NanoViricides Frequently Asked Questions

Are investors shorting NanoViricides?

NanoViricides saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 353,000 shares, a decline of 19.0% from the May 31st total of 435,700 shares. Based on an average daily volume of 67,300 shares, the short-interest ratio is presently 5.2 days. Currently, 3.2% of the shares of the company are short sold.
View NanoViricides' Short Interest
.

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSEAMERICAN:NNVC) issued its earnings results on Tuesday, May, 17th. The company reported ($0.16) earnings per share for the quarter.
View NanoViricides' earnings history
.

When did NanoViricides' stock split? How did NanoViricides' stock split work?

NanoViricides shares reverse split on Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of NanoViricides stock prior to the reverse split would have 5 shares after the split.

Who are NanoViricides' key executives?

NanoViricides' management team includes the following people:
  • Dr. Anil R. Diwan Ph.D., Exec. Chairman, Pres, CEO & Sec. (Age 63, Pay $400k)
  • Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA, Chief Financial Officer (Age 63, Pay $129.6k)
  • Dr. Randall W. Barton Ph.D., Chief Scientific Officer & Chief Regulatory Officer (Age 75)

What other stocks do shareholders of NanoViricides own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NanoViricides investors own include Cytosorbents (CTSO), Rekor Systems (REKR), Inovio Pharmaceuticals (INO), Micron Technology (MU), Gilead Sciences (GILD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), iBio (IBIO) and Moderna (MRNA).

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NNVC."

How do I buy shares of NanoViricides?

Shares of NNVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $1.89.

How much money does NanoViricides make?

NanoViricides (NYSEAMERICAN:NNVC) has a market capitalization of $21.84 million. The company earns $-8,820,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does NanoViricides have?

NanoViricides employs 17 workers across the globe.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Dr, SHELTON, CT 06484-6153, United States. The official website for NanoViricides is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at info@nanoviricides.com, or via fax at 203-859-5095.

This page (NYSEAMERICAN:NNVC) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.